{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:55:41Z","timestamp":1783641341649,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.04.061","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:39:02Z","timestamp":1683074342000},"page":"3518-3524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sustained antibody persistence for at least 15\u00a0years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-4197","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Beran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-426X","authenticated-orcid":false,"given":"Maria","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pammolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Galgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.04.061_b0005","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1080\/21645515.2016.1218098","article-title":"Tick-borne encephalitis: What travelers should know when visiting an endemic country","volume":"12","author":"Chrdle","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.04.061_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.01.004","article-title":"Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment","volume":"62","author":"Riccardi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.vaccine.2023.04.061_b0015","first-page":"241","article-title":"Vaccines against tick-borne encephalitis: WHO position paper","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2023.04.061_b0020","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/ene.13356","article-title":"EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis","volume":"24","author":"Taba","year":"2017","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.vaccine.2023.04.061_b0025","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3390\/microorganisms10071283","article-title":"Recommendations to improve tick-borne encephalitis surveillance and vaccine uptake in Europe","volume":"10","author":"Kunze","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2023.04.061_b0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/14760584.2017.1358620","article-title":"Systematic literature review comparing rapid 3-dose administration of the GSK tick-borne encephalitis vaccine with other primary immunization schedules","volume":"16","author":"Galgani","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.061_b0035","unstructured":"Bundesministerium Soziales, Gesundheit, Pflege und Konsumentenschutz. Gebrauchsinformationen der Impfstoffe im kostenfreien Impfprogramm - Gebrauchsinformation Encepur 0,5 ml, https:\/\/www.sozialministerium.at\/Themen\/Gesundheit\/Impfen\/Gebrauchsinformationen-der-Impfstoffe-im-kostenfreien-Impfprogramm.html; [accessed 24 August 2022]."},{"key":"10.1016\/j.vaccine.2023.04.061_b0040","unstructured":"Compendium.ch - Bavarian Nordic Switzerland AG. Encepur N, Encepur N Kinder (Swissmedic-genehmigte Fachinformation), https:\/\/compendium.ch\/product\/105785-encepur-n-inj-susp\/mpro; [accessed 24 August 2022]."},{"key":"10.1016\/j.vaccine.2023.04.061_b0045","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1080\/21645515.2019.1700712","article-title":"Predicted long-term antibody persistence for a tick-borne encephalitis vaccine: results from a modeling study beyond 10 years after a booster dose following different primary vaccination schedules","volume":"16","author":"Costantini","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.04.061_b0050","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.ttbdis.2021.101779","article-title":"Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review","volume":"12","author":"Steffen","year":"2021","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2023.04.061_b0055","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.vaccine.2017.12.081","article-title":"Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence","volume":"37","author":"Beran","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.061_b0060","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.vaccine.2006.10.028","article-title":"Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule","volume":"25","author":"Sch\u00f6ndorf","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.061_b0065","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1016\/j.vaccine.2014.06.028","article-title":"Five year follow-up after a first booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety","volume":"32","author":"Beran","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.061_b0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0264-410X(91)90315-W","article-title":"Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization","volume":"9","author":"Klockmann","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.061_b0075","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/S0264-410X(03)00421-3","article-title":"Safety, immunogenicity and tolerability of a new pediatric tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer","volume":"21","author":"Zent","year":"2003","journal-title":"Vaccine"},{"issue":"Suppl 37","key":"10.1016\/j.vaccine.2023.04.061_b0080","first-page":"134","article-title":"TBE booster immunization in adults\u2013first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer","volume":"293","author":"Zent","year":"2004","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.vaccine.2023.04.061_b0085","doi-asserted-by":"crossref","first-page":"8264","DOI":"10.1016\/j.vaccine.2020.11.002","article-title":"Understanding immunosenescence and its impact on vaccination of older adults","volume":"38","author":"Allen","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.061_b0090","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ttbdis.2018.02.007","article-title":"Self-reported tick-borne encephalitis (TBE) vaccination coverage in Europe: Results from a cross-sectional study","volume":"9","author":"Erber","year":"2018","journal-title":"Ticks Tick Borne Dis"},{"key":"10.1016\/j.vaccine.2023.04.061_b0095","unstructured":"Finnish Institute for Health and Welfare. Infectious diseases and vaccination - TBE, or \u2018tick vaccine\u2019 - Dosage and schedule, https:\/\/thl.fi\/en\/web\/infectious-diseases-and-vaccinations\/vaccines-a-to-z\/tbe-or-tick-vaccine-#dosage; [accessed 24 August 2022]."},{"key":"10.1016\/j.vaccine.2023.04.061_b0100","unstructured":"Infovac. M\u00e9ningo-enc\u00e9phalite \u00e0 tiques - Vaccin contre la m\u00e9ningo-enc\u00e9phalite \u00e0 tiques, https:\/\/www.infovac.ch\/fr\/les-vaccins\/par-maladie\/meningo-encephalite-a-tiques; [accessed 24 August 2022]."},{"key":"10.1016\/j.vaccine.2023.04.061_b0105","doi-asserted-by":"crossref","first-page":"e061228","DOI":"10.1136\/bmjopen-2022-061228","article-title":"Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006\u20132020","volume":"12","author":"Zens","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.04.061_b0110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/vaccines8030451","article-title":"Tick-borne encephalitis virus: A quest for better vaccines against a virus on the rise","volume":"8","author":"Kubinski","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.04.061_b0115","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2017.03.059","article-title":"Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults","volume":"35","author":"Konior","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:26:46Z","timestamp":1759404406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":23,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23004851"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained antibody persistence for at least 15\u00a0years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}